Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

World Journal of Gastroenterology

Volumn 20, Issue 20, 2014, Pages 6102-6112

  Hohla, Florian ^a,b   Winder, Thomas ^c   Greil, Richard ^a   Rick, Ferenc G ^d,e   Block, Norman L ^e,f   Schally, Andrew V ^e,f  

^a III rd Medical Department with Hematology Medical Oncology Hemostasis Rheumatology and Infectious Diseases Oncologic Center Center for Clinical Cancer and Immunology Trials   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Cytotoxic analogs; Epidermal growth factor receptor; Gastrin releasing peptide; Growth hormone releasing hormone; Luteinizing hormone releasing hormone; Peptide receptors; Targeted treatment; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; AN 162; BEVACIZUMAB; BOMBESIN; BOMBESIN ANTAGONIST; CAPECITABINE; CETUXIMAB; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2, 7 DISULFIDE 2 PYRROLINODOXORUBICIN; DRUG ANALOG; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GASTRIN RELEASING PEPTIDE; GONADORELIN; GONADORELIN [6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GROWTH HORMONE RELEASING FACTOR; OXALIPLATIN; PANITUMUMAB; RC 3095; REGORAFENIB; SOMATOSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ZOPTARELIN DOXORUBICIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDE FRAGMENT; RECEPTOR; VASCULOTROPIN A;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; CHEMISTRY; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901489422     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i20.6102     Document Type: Article

References (80)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S. Characterizing medical care by disease phase in metastatic colorectal cancer. Am J Manag Care 2011; 17 Suppl 5 Developing: SP20-SP25 [PMID: 21711074]
3. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844 [PMID: 7683111 DOI: 10.1038/362841a0]
4. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-680 [PMID: 15705858]
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
6. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in firstline treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786 [PMID: 17947725 DOI: 10.1200/JCO.2007.11.3357]
7. Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013; 49: 1236-1245 [PMID: 23352604 DOI: 10.1016/ j.ejca.2012.12.011]
8. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105: 58-64 [PMID: 21673685 DOI: 10.1038/bjc.2011.201]
9. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529 [PMID: 18640933 DOI: 10.1200/JCO.2007.15.4138]
10. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930]
11. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544 [PMID: 17442997 DOI: 10.1200/JCO.2006.09.6305]
12. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37 [PMID: 23168366 DOI: 10.1016/S1470-2045(12)70477-1]
13. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009; 9: 263-271 [PMID: 19236257 DOI: 10.1517/14712590802666397]
14. Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer 2013; 12: 73-85 [PMID: 23102896 DOI: 10.1016/j.clcc.2012.08.001]
15. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748 [PMID: 18669461 DOI: 10.1200/ JCO.2007.15.5416]
16. Taylor AP, Osorio L, Craig R, Raleigh JA, Ying Z, Goldenberg DM, Blumenthal RD. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin Cancer Res 2002; 8: 1213-1222 [PMID: 11948135]
17. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009; 2: re1 [PMID: 19244214 DOI: 10.1126/scisignal.259re1]
18. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506 [PMID: 22949147 DOI: 10.1200/JCO.2012.42.8201]
19. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-255 [PMID: 21170960 DOI: 10.1002/ijc.25864]
20. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312 [PMID: 23177514 DOI: 10.1016/S0140-6736(12)61900-X]
21. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5: 203-220 [PMID: 17374728 DOI: 10.1158/1541-7786.MCR-06-0404]
22. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]
23. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515 [PMID: 17998284 DOI: 10.1093/annonc/mdm496]
24. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169 [PMID: 17375050 DOI: 10.1038/sj.bjc.6603685]
25. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145 [PMID: 17940504 DOI: 10.1038/sj.bjc.6604009]
26. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379 [PMID: 18202412 DOI: 10.1200/ JCO.2007.12.5906]
27. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]
28. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/ NEJMoa0805019]
29. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-1546 [PMID: 21228335 DOI: 10.1093/annonc/mdq632]
30. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/ JCO.2008.20.8397]
31. Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller J, Kahl C, Stintzing S. Randomized comparison of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol 2013; 31: abstract LBA3506
32. Gravalos C, Cassinello J, García-Alfonso P, Jimeno A. Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol 2010; 74: 16-26 [PMID: 19616446 DOI: 10.1016/j.critrevonc.2009.06.005]
33. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]
34. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]
35. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713 [PMID: 20921462 DOI: 10.1200/JCO.2009.27.6055]
36. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034 [PMID: 24024839 DOI: 10.1056/ NEJMoa1305275]
37. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Yu H, Oliner KS, Go WY. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) meta-static colorectal cancer (mCRC). J Clin Oncol 2013; 31: abstr 3631
38. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008; 60: 1-42 [PMID: 18055507 DOI: 10.1124/ pr.107.07108]
39. Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim Biophys Acta 2006; 1766: 23-41 [PMID: 16490321 DOI: 10.1016/j.bbcan.2006.01.003]
40. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001; 22: 248-291 [PMID: 11587553 DOI: 10.1006/frne.2001.0217]
41. Schally AV, Szepeshazi K, Nagy A, Comaru-Schally AM, Halmos G. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 2004; 61: 1042-1068 [PMID: 15112052 DOI: 10.1007/ s00018-004-3434-3]
42. Corral RS, Iñiguez MA, Duque J, López-Pérez R, Fresno M. Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. Oncogene 2007; 26: 958-969 [PMID: 16909108 DOI: 10.1038/sj.onc.1209856]
43. Thomas RP, Hellmich MR, Townsend CM, Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev 2003; 24: 571-599 [PMID: 14570743]
44. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316: 823-826 [PMID: 2993906]
45. Glover SC, Tretiakova MS, Carroll RE, Benya RV. Increased frequency of gastrin-releasing peptide receptor gene mutations during colon-adenocarcinoma progression. Mol Carcinog 2003; 37: 5-15 [PMID: 12720295 DOI: 10.1002/mc.10117]
46. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001; 22: 689-699 [PMID: 11311741]
47. Spindel ER, Giladi E, Segerson TP, Nagalla S. Bombesinlike peptides: of ligands and receptors. Recent Prog Horm Res 1993; 48: 365-391 [PMID: 8382830]
48. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 1999; 276: G655-G665 [PMID: 10070042]
49. Chave HS, Gough AC, Palmer K, Preston SR, Primrose JN. Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer 2000; 82: 124-130 [PMID: 10638978 DOI: 10.1054/bjoc.1998.0888]
50. Ferris HA, Carroll RE, Lorimer DL, Benya RV. Location and characterization of the human GRP receptor expressed by gastrointestinal epithelial cells. Peptides 1997; 18: 663-672 [PMID: 9213359]
51. Patel O, Dumesny C, Giraud AS, Baldwin GS, Shulkes A. Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor. Biochem Pharmacol 2004; 68: 2129-2142 [PMID: 15498503 DOI: 10.1016/ j.bcp.2004.08.009]
52. Preston SR, Woodhouse LF, Jones-Blackett S, Miller GV, Primrose JN. High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. Br J Cancer 1995; 71: 1087-1089 [PMID: 7734305]
53. Radulovic SS, Milovanovic SR, Cai RZ, Schally AV. The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc Soc Exp Biol Med 1992; 200: 394-401 [PMID: 1352046]
54. Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle 2012; 11: 2518-2525 [PMID: 22751419 DOI: 10.4161/cc.20900]
55. Saurin JC, Rouault JP, Abello J, Berger F, Remy L, Chayvialle JA. High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer. Eur J Cancer 1999; 35: 125-132 [PMID: 10211100]
56. Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle 2010; 9: 1738-1741 [PMID: 20473035]
57. Casanueva FF, Perez FR, Casabiell X, Camiña JP, Cai RZ, Schally AV. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc Natl Acad Sci USA 1996; 93: 1406-1411 [PMID: 8643644]
58. Radulovic S, Miller G, Schally AV. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res 1991; 51: 6006-6009 [PMID: 1682040]
59. Reile H, Cai R, Armatis P, Schally A. New antagonists of bombesin gastrin-releasing Peptide with C-terminal leu-psi-(ch2n)tac-nh2. Int J Oncol 1995; 7: 749-754 [PMID: 21552898]
60. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G, Szalontay L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 2011; 108: 3755-3760 [PMID: 21321192 DOI: 10.1073/pnas.1018086108]
61. Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncol 1994; 33: 693-701 [PMID: 7946450]
62. Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, Pereira AS, Richter M, Souza F, da Rocha AB, Souza FH, Pohlmann P, De Nucci G. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24: 403-412 [PMID: 16505950 DOI: 10.1007/ s10637-006-6886-5]
63. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218: 585-587 [PMID: 6812220]
64. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4: 33-43 [PMID: 18084344 DOI: 10.1038/ncpendmet0677]
65. Fürstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302 [PMID: 12067807]
66. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, Szepeshazi K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 2002; 99: 11866-11871 [PMID: 12186980 DOI: 10.1073/pnas.182433099]
67. Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, Krishan A, Kurtoglu M, Chandna S, Aigner E, Datz C. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 2009; 8: 3149-3156 [PMID: 19755849]
68. Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle 2012; 11: 4203-4210 [PMID: 23095641 DOI: 10.4161/cc.22498]
69. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Köster F, Kovitz K, Groot K, Zarandi M, Kanashiro CA. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 2005; 102: 17424-17429 [PMID: 16299104 DOI: 10.1073/ pnas.0506844102]
70. Hohla F, Moder A, Mayrhauser U, Hauser-Kronberger C, Schally AV, Varga JL, Zarandi M, Buchholz S, Huber R, Aigner E, Ritter M, Datz C. Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. Int J Oncol 2008; 33: 137-143 [PMID: 18575759]
71. Engel J, Emons G, Pinski J, Schally AV. AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 2012; 21: 891-899 [PMID: 22577891 DOI: 10.1517/13543784.2 012.685128]
72. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004; 15: 300-310 [PMID: 15350601 DOI: 10.1016/j.tem.2004.07.002]
73. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997; 20: 348-367 [PMID: 9294784]
74. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16: 427-442 [PMID: 8521788]
75. Hohla F, Buchholz S, Schally AV, Krishan A, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C, Seitz S. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett 2010; 294: 35-42 [PMID: 20156671 DOI: 10.1016/ j.canlet.2010.01.018]
76. Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B, Feil A, Kiaris H, Nagy A. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res 2002; 62: 781-788 [PMID: 11830533]
77. Cai RZ, Karashima T, Guoth J, Szoke B, Olsen D, Schally AV. Superactive octapeptide somatostatin analogs containing tryptophan at position 1. Proc Natl Acad Sci USA 1987; 84: 2502-2506 [PMID: 2882520]
78. Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1998; 95: 1794-1799 [PMID: 9465096]
79. Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 1999; 20: 1247-1262 [PMID: 10573298]
80. Szepeshazi K, Schally AV, Halmos G. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 2007; 30: 1485-1492 [PMID: 17487370]